LADAR 6000 offers good visual outcomes

Article

The LADAR 6000 excimer laser with high-speed ablation (Alcon) offers excellent visual outcomes, according to Ángel López Castro of Spain, speaking at the Alcon symposium.

The LADAR 6000 excimer laser with high-speed ablation (Alcon) offers excellent visual outcomes, according to Ángel López Castro of Spain, speaking at the Alcon symposium.

Dr López Castro conducted a study comparing conventional and custom treatments using the LADAR system. A total of 115 eyes were enrolled in the study with 110 receiving the custom LASIK and 14 the conventional treatment.

At three months, two-thirds of eyes in the custom group were within 0.25 D mean refractive spherical equivalent (MRSE) of their intended target, compared with around half of those in the conventional treatment group. 70% of eyes achieved a postoperative uncorrected visual acuity (UCVA) equal to or better than their preoperative best corrected visual acuity (BCVA) as opposed to just 57% of the conventionally treated group.

López Castro discussed what he sees as the benefits of the new system: more surgeon control, enhanced ergonomics, improved patient comfort. Finally he remarked on the LADAR 6000's speed; it is 50% faster than Alcon's previous system. Treatments can now be completed in less than 60 seconds, which may offer potential postoperative benefits.

Dr López Castro concluded that the LADAR 6000 is able to offer good visual outcomes for the patient whilst also offering the surgeon a more efficient, simpler-to-use system.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.